Spyre Therapeutics (“Spyre” or “The Company”) (NASDAQ: SYRE) is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. Spyre’s pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23.